Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | SPR | P35270 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523654 | 1.00 | NOTUM (1.00) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL10167044 | 1.00 | NOTUM (1.00) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL20462830 | 0.86 | NOTUM (0.75) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL8057268 | 0.84 | NOTUM (0.73) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL1865732 | 0.84 | NOTUM (0.73) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL30366703 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21172540 | 0.83 | NOTUM (0.71) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL21172704 | 0.83 | NOTUM (0.71) | NOTUMALDH1A1NPC1PKMSMN1; SMN2 | |
| SCHEMBL30366447 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1825815 | 0.83 | NOTUM (0.71) | NOTUMSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708267-B2 | Activators of human pyruvate kinase | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-07-18 | — | — | US | claimed |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2013-05-02 | — | — | US | claimed |
| EP-2563761-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2013-03-06 | — | — | EP | claimed |
| WO-2011137089-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | claimed |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| WO-2002102785-A1 | NOVEL BICYCLIC ISOXAZOLINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| EP-0656003-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-07 | — | — | EP | disclosed |
| EP-0409949-B1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | ICI PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| CN-1086819-A | Novel compounds having 5-hydroxytryptamine receptor antagonistic activity | SMITHKLINE BEECHAM PLC (GB) | 1994-05-18 | — | — | CN | disclosed |
| WO-1994004533-A1 | CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-03-03 | — | — | WO | disclosed |
| US-5185452-A | Antidiabetic agents; aldose reductase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-09 | — | — | US | disclosed |
| EP-0409949-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | ICI PLC (GB) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990008763-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | NOTUM 1324/4885ALDH1A1 514/4885NPC1 52/4885 |
| US-20130109672-A1 | ACTIVATORS OF HUMAN PYRUVATE KINASE | PDK2, PDK1, PKLR | NOTUM 4742/4885ALDH1A1 1009/4885NPC1 2897/4885 |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | NOTUM 2496/4885ALDH1A1 1206/4885NPC1 2521/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | NOTUM 4317/4885ALDH1A1 967/4885NPC1 4325/4885 |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | CXCR1, ZC3HAV1L, ZC3HAV1 | NOTUM 4724/4885ALDH1A1 1636/4885NPC1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.